

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				<i>Complete if Known</i>
				Application Number 10/772,090
				Filing Date February 3, 2004
				First Named Inventor Margaret H. Baron
				Art Unit 1646
				Examiner Name Z. C. Howard
Sheet	1	of	4	Attorney Docket Number HUIP-P02-060

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AF1	2002/0015702	02-07-2002	Burkly et al.	
	AG1	2005/0080138A1	04-14-2005	Guicherit et al.	
	AH1	5,681,278	10-28-1997	Igo et al.	
	AI1	5,789,543	08-04-1998	Ingham et al.	
	AJ1	5,837,538	11-17-1998	Scott et al.	
	AK1	6,027,882	02-22-2000	Scott et al.	
	AL1	6,165,747	12-26-2000	Ingham et al.	
	AM1	6,172,200	01-09-2001	Scott et al.	
	AN1	6,261,786	07-17-2001	Marigo et al.	
	AO1	6,271,363	08-07-2001	Ingham et al.	
	AP1	6,384,192	05-07-2002	Ingham et al.	
	AQ1	6,429,354	08-06-2002	Scott et al.	
	AR1	6,432,970	08-13-2002	Beachy et al.	
	AS1	6,545,005	04-08-2003	Baxter et al.	
	AT1	6,551,782	04-22-2003	Scott et al.	
	AU1	6,552,016	04-22-2003	Baxter et al.	
	AV1	6,576,237	06-10-2003	Ingham et al.	
	AW1	6,607,913	08-19-2003	Ingham et al.	
	AX1	6,610,507 A1	08-26-2003	Scott et al.	
	AY1	6,610,656	08-26-2003	Ingham et al.	
	AZ1	6,613,798	09-02-2003	Jeffrey Porter	
	AA2	6,630,148	10-07-2003	Ingham et al.	
	AB2	6,664,075-A1	12-16-2003	Ingham et al.	
	AC2	6,867,216	03-15-2005	Beachy et al.	
	AD2	6,884,775	04-26-2005	Tabin et al.	
	AE2	6,921,646 A1	07-26-2005	Scott et al.	
	AF2	6,946,257	09-20-2005	Scott et al.	
	AG2	7,060,450	06-13-2006	Tabin et al.	
	AH2	7,144,732-A1	12-05-2006	Ingham et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	BE	WO-00/18428	04-06-2000	BIOGEN, INC.		
	BF	WO-00/15246	03-23-2000	PRESIDENT AND FELLOWS OF HARVARD COLLEGE		
	BG	WO 00/25725	05-11-2000	BIOGEN, INC.		
	BH	WO-00/41545	07-20-2000	ONTOGENY		
	BI	WO 01/19800 A2	03-22-2001	CURIS, INC.		
	BJ	WO 01/26644 A2	04-19-2001	CURIS, INC.		
	BK	WO 01/74344 A2	10-11-2001	CURIS, INC.		
	BL	WO-02/30462	04-18-2002	CURIS, INC.		
	BM	WO-02/80952-A2	10-17-2002	LORAN-TIS LIMITED		
	BN	WO-03/011219	02-13-2003	CURIS, INC.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	2	of	4	Attorney Docket Number	HUIP-P02-060

	BO	WO-95/23223	08-31-1995	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK		
	BP	WO-96/17924	06-13-1996	THE JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE		

Examiner Signature	/Zachary Howard/	Date Considered	10/03/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CD2	Ballara, S. C. et al. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int. J. Exp. Path. 80, 235-250 (1999).	
	CE2	Banai, S. et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89, 2183-2189 (May 1994).	
	CF2	Battler, A. et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J. Am. Coll Cardiol. 22, 2001-2006 (Dec. 1993).	
	CG2	Beck, L. Jr. & D'Amore, P. A. Vascular development: cellular and molecular regulation. FASEB J. 11, 365-373 (April 1997).	
	CH2	Berger et al. Chromosomes in Kidney, Ureter, and Bladder Cancer. Cancer Genetics and Cytogenetics 23: 1-24 (1986)	
	CI2	Bhusham, M. et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br. J. Dermatol. 141, 1054-1060 (Dec. 1994).	
	CJ2	Cairns et al. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8: 1083-1085 (1992)	
	CK2	Carter et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. PNAS 87: 8751-8755 (1990)	
	CL2	Chatel et al. Int. J. Cancer. Vol. 121, 2622-2627 (2007)	
	CM2	Cherrington, J. M. et al. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 79, 1-38 (2000).	
	CN2	D'Amato. Angiogenesis Inhibition in Age-related Macular Degeneration. Ophthalmology 102, 1261-1262 (Sept. 1995).	
	CO2	Dahmane, et al., "Activation of the transcription factor Gli 1 and the Sonic hedgehog signalling pathways in skin tumours", Nature, vol. 389, pp. 876-881 (1997)	
	CP2	Dalbagni et al. Genetic alterations in bladder cancer. Lancet 342: 469-471 (1993)	
	CQ2	Dermer, Gerald B., "The Last Word - Another Anniversary for the War on Cancer", Bio/Technology, Vol. 12, page 320 (1994)	
	CR2	Dillman, Robert O., "Monoclonal Antibodies for Treating Cancer", Annals of Internal Medicine,	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	3	of	4	Attorney Docket Number	HUIP-P02-060

		111: pp. 592-603 (1989)	
	CS2	Engler, D. A. Use of vascular endothelial growth factor for therapeutic angiogenesis. Circulation 94, 1496-1498 (1 Oct. 1996).	
	CT2	Fan, H. et al. Myc-epitope tagged proteins detected with the 9E10 antibody in immunofluorescence and immunoprecipitation assays but not in western blot analysis. Biochem. Cell Biol. 76, 125-128 (1998).	
	CU2	Feng et al., "Overexpression of Hedgehog Signaling Molecules and Its Involvement in the Proliferation of Endometrial Carcinoma Cells", Human Cancer Biology, Vol. 13, pp. 1389-1398 (2007)	
	CV2	Fong, T. A. T. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99-106 (Jan. 1999).	
	CW2	Freshney, R. Ian, "Culture of Animal Cells, A Manual of Basic Technique", Alan R. Liss, Inc., pages 3-4 (1983)	
	CX2	Fujita, E. et al., "Involvement of Sonic Hedgehog in the Cell Growth of LK-2 Cells, Human Lung Squamous Carcinoma Cells", Biochem. Biophys. Res. Comm., 238, pp. 658-664, (1997)	
	CY2	Gibas et al. Nonrandom Chromosomal Changes in Transitional Cell Carcinoma of the Bladder. Cancer Research 44:1257-1264 (1984)	
	CZ2	Goodrich, L. V. et al. Altered neural cell fate and medulloblastoma in mouse patched mutants. Science 277, 1109-1113 (1997).	
	CA3	Green, et al., "Basal cell carcinoma development is associated with induction of the expression of the transcription factor Gli-1", British Journal of Dermatology, vol. 139, pp. 911-915, (1998)	
	CB3	Greenspan, N.S. and Di Cera, E., "Defining epitopes: It's not as easy as it seems," Nature Biotechnology, 17:936-937 (1999).	
	CC3	Hammerschmidt, M. et al: "The world according to hedgehog", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 13, no. 1, 1997, pages 14-21	
	CD3	Heijstek, et al., "Mouse Models of Colorectal Cancer and Liver Metastases", Digestive Surgery, 22: pp. 16-25 (2005)	
	CE3	Huang et al., "Activation of the hedgehog pathway in human hepatocellular carcinomas", Carcinogenesis, Vol. 27(7), pp. 1334-1340 (2006)	
	CF3	Ingham, P.W. Signaling by hedgehog family proteins in Drosophila and vertebrate development. Curr. Opin. Genet. Dev. 5, 492-498 (1995).	
	CG3	Jain, Rakesh K., "Barriers to Drug Delivery in Solid Tumors", Scientific American, pp. 58-65 (July 1994)	
	CH3	Kenyon, B. M. et al. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37, 1625-1632 (1996).	
	CI3	Klagsbrun, M. & D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217-239 (1991).	
	CJ3	Klohs, W. D. & Hamby, J. M. Antiangiogenic agents. Curr. Opin. Biotechnol. 10, 544-549 (Dec. 1999).	
	CK3	Kobaeck-Larsen, et al., "Review of Colorectal Cancer and Its Metastases in Rodent Models: Comparative Aspects with Those in Humans", Comparative Medicine, 50(1): pp. 16-26 (2000)	
	CL3	Kornowski, R. et al. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 101, 454-458 (Feb. 2000).	
	CM3	McGarvey, T.W. et al. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17, 1167-1172 (1998).	
	CN3	Merseburger et al., "Tissue microarrays: applications in urological cancer research", World J. Urol., Vol. 24, pp. 579-584 (2006)	
	CO3	Ozaki, H. et al. Blockade of vascular endothelial cell growth factor receptor signaling is	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	4	of	4	Attorney Docket Number	HUIP-P02-060

		sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156, 697-707 (Feb. 2000).	
	CP3	Passaniti, A. et al. Methods in Laboratory Investigation: A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor. Lab. Invest. 67, 519-528 (1992).	
	CQ3	Peacock, D. J. et al. A Novel Angiogenesis Inhibitor Suppresses Rat Adjuvant Arthritis. Cell Immunol. 160, 178-184 (Feb. 1995).	
	CR3	Perrimon, N. Hedgehog and beyond. Cell 80, 517-520 (1995).	
	CS3	Pettet et al., "On the role of angiogenesis in wound healing," Proc. R. Soc. Lond., B 263:1487-1493 (1996)	
	CT3	Pola et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7, 706-711 (2001).	
	CU3	Roberts, et al., "Amplification of the gli Gene in Childhood Sarcomas", Cancer Research, vol. 49, pp. 5407-5413 (1989)	
	CV3	Sanchez, et al., "Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling", PNAS, 101(34), pp. 12561-12566 (2004)	
	CW3	Smeets, W. et al. Chromosomal Analysis of Bladder Cancer. III. Nonrandom Alterations. Cancer Genetics and Cytogenetics 29, 29-41 (1987).	
	CX3	Stancovski, I., et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci, USA, 88:8691-8695 (1991).	
	CY3	Stecca, B. et al., "The Therapeutic Potential of Modulators of the Hedgehog-Gli Signaling Pathway", Journal of Biology, Vol. 1:2(9) (2002)	
	CZ3	Talpale, et al., "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", Letters to Nature, 406: pp. 1005-1009	
	CA4	Tribbick, G., "Multipin Peptide Libraries for Antibody and Receptor Epitope Screening and Characterization", Journal of Immunological Methods, vol. 267, pages 27-35 (2002)	
	CB4	Unwin et al., "Urological malignancies and the proteomic-genomic interface", Electrophoresis, Vol. 20, pp. 3629-3637 (1999)	
	CC4	Weiner, Louis M., "An Overview of Monoclonal Antibody Therapy of Cancer", Seminars in Oncology, Vol. 25:4, Suppl. 12, pp. 41-50 (August 1999)	
	CD4	Welt et al., "Antibodies in the Therapy of Colon Cancer", Seminars in Oncology, 26(6): pp. 683-690 (1999)	
	CE4	Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-2189 (April 2000).	
	CF4	Zhu, Z. & Witte, L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 17, 195-212 (1999).	

Examiner Signature	/Zachary Howard/	Date Considered	10/03/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.